Correlation Between Liquidia Technologies and Halozyme Therapeutics
Can any of the company-specific risk be diversified away by investing in both Liquidia Technologies and Halozyme Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Liquidia Technologies and Halozyme Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Liquidia Technologies and Halozyme Therapeutics, you can compare the effects of market volatilities on Liquidia Technologies and Halozyme Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Liquidia Technologies with a short position of Halozyme Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Liquidia Technologies and Halozyme Therapeutics.
Diversification Opportunities for Liquidia Technologies and Halozyme Therapeutics
0.44 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Liquidia and Halozyme is 0.44. Overlapping area represents the amount of risk that can be diversified away by holding Liquidia Technologies and Halozyme Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Halozyme Therapeutics and Liquidia Technologies is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Liquidia Technologies are associated (or correlated) with Halozyme Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Halozyme Therapeutics has no effect on the direction of Liquidia Technologies i.e., Liquidia Technologies and Halozyme Therapeutics go up and down completely randomly.
Pair Corralation between Liquidia Technologies and Halozyme Therapeutics
Given the investment horizon of 90 days Liquidia Technologies is expected to generate 1.47 times more return on investment than Halozyme Therapeutics. However, Liquidia Technologies is 1.47 times more volatile than Halozyme Therapeutics. It trades about 0.06 of its potential returns per unit of risk. Halozyme Therapeutics is currently generating about 0.03 per unit of risk. If you would invest 745.00 in Liquidia Technologies on November 9, 2024 and sell it today you would earn a total of 851.00 from holding Liquidia Technologies or generate 114.23% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Liquidia Technologies vs. Halozyme Therapeutics
Performance |
| Timeline |
| Liquidia Technologies |
| Halozyme Therapeutics |
Liquidia Technologies and Halozyme Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Liquidia Technologies and Halozyme Therapeutics
The main advantage of trading using opposite Liquidia Technologies and Halozyme Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Liquidia Technologies position performs unexpectedly, Halozyme Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Halozyme Therapeutics will offset losses from the drop in Halozyme Therapeutics' long position.| Liquidia Technologies vs. Biomarin Pharmaceutical | Liquidia Technologies vs. Vaxcyte | Liquidia Technologies vs. Legend Biotech Corp | Liquidia Technologies vs. Bio Techne Corp |
| Halozyme Therapeutics vs. Agios Pharm | Halozyme Therapeutics vs. Insmed Inc | Halozyme Therapeutics vs. Ultragenyx | Halozyme Therapeutics vs. Biomarin Pharmaceutical |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Complementary Tools
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |